The Infarmed authority has announced the suspension of a wholesale distributor following the identification of non-compliances with good distribution practices, as reported by the German competent authority. The notification was issued through Infarmed’s official website.
In response to the situation, the medication authority advises that entities should refrain from commercializing medicines from CannaPhytica BioMed GmbH, a biotechnology company specializing in the medical cannabis industry.
Entities that have acquired or have been contacted by this distributor to purchase drugs are cautioned not to commercialize these products and are required to report the matter to Infarmed.
